Lepu Biopharma Says AstraZeneca Begins Phase 3 Trial of CMG901 Cancer Therapy; Shares Jump 7%
MT Newswires Live
Mar 11
Lepu Biopharma Co (HKG:2157) said AstraZeneca has initiated a Phase 3 clinical study of its antibody-drug conjugate candidate CMG901, triggering a milestone payment of $45 million under their collaboration agreement, according to a Wednesday Hong Kong bourse filing.
The trial is evaluating sonesitatug vedotin (AZD0901) in combination with capecitabine, with or without rilvegostomig, for first-line treatment of Claudin 18.2-positive, HER2-negative advanced or metastatic gastric and related cancers.
CMG901 was developed through KYM Biosciences, a joint venture between Lepu Biopharma and Keymed Biosciences (HKG:2162).
Lepu Biopharma's shares jumped nearly 7% in early-morning trade on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.